A ferric chloride induced arterial injury model used as haemostatic effect model

Haemophilia

Volumn 16, Issue 1, 2010, Pages

  Moller, F ^a   Tranholm, M ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

FeCl3 induced injury; Haemophilic mice; Haemostatic effect model

Indexed keywords

FERRIC CHLORIDE; HEMOSTATIC AGENT; PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTICLE; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; HEMOSTASIS; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS; WILD TYPE;

ANIMALS; CAROTID ARTERY DISEASES; CHLORIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR IX; FACTOR VIII; FERRIC COMPOUNDS; HEMOPHILIA A; HEMOSTASIS; MICE; MICE, KNOCKOUT; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 73949088476     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02133.x     Document Type: Article

References (42)

1. Hough C, Kamisue S, Cameron C. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. Thromb Haemost 2002, 87:659-65.
2. Brooks M. A review of canine inherited bleeding disorders: biochemical and molecular strategies for disease characterization and carrier detection. J Hered 1999, 90:112-8.
3. Dodds WJ. Hereditary and acquired hemorrhagic disorders in animals. Prog Hemost Thromb 1974, 2:215-47.
4. Tomokiyo K, Teshima K, Nakatomi Y. Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B. Thromb Res 2001, 102:363-74.
5. Erhardtsen E, Ezban M, Madsen MT. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995, 6:388-94.
6. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003, 102:3615-20.
7. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997, 90:3962-6.
8. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995, 10:119-21.
9. Kingdon HS, Hassell TM. Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions. Blood 1981, 58:868-72.
10. Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 1982, 60:727-30.
11. Kristensen AT, Madsen MT, Nielsen GN, Ezban M. Recombinant human FVIIa dose dependeltly shortens the bleeding time in a rabbit model of antibody induced hamophilia A. Thromb Haemost 1999, 82:1038.
12. Giles AR, Tinlin S, Hoogendoorn H, Fournel MA, Ng P, Pancham N. In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency). Blood 1988, 72:335-9.
13. Huang ZS, Lee TK, Teng CM, Wang CY, Huang LH, Chang CH. A simple method to create carotid endothelial laceration and acute platelet thrombus in vivo in guinea-pig. Thromb Res 1990, 60:109-19.
14. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 2000, 95:577-80.
15. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002, 8:1175-81.
16. Kusada A, Isogai N, Cooley BC. Electric injury model of murine arterial thrombosis. Thromb Res 2007, 121:103-6.
17. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990, 60:269-80.
18. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999, 94:187-97.
19. Schwarz M, Meade G, Stoll P. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006, 99:25-33.
20. Iwatsuki Y, Kawasaki T, Hayashi K, Moritani Y, Nii T, Miyata K. Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice. Thromb Haemost 2004, 92:1221-8.
21. Nishida M, Matsuno H, Kozawa O. tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor. J Cardiovasc Pharmacol 2000, 36:770-5.
22. Hechler B, Magnenat S, Zighetti ML. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4′,4′',4′''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis -benzene-1,3-disulfonic acid octasodium salt]. J Pharmacol Exp Ther 2005, 314:232-43.
23. Sorg H, Hoffmann JN, Menger MD, Lindenblatt N, Goehring P, Vollmar B. Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model. Thromb Haemost 2006, 96:371-7.
24. Heran C, Morgan S, Kasiewski C. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. Eur J Pharmacol 2000, 389:201-7.
25. Ni H, Denis CV, Subbarao S. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000, 106:385-92.
26. Falati S, Liu Q, Gross P. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003, 197:1585-98.
27. Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999, 93:1825-30.
28. Ovlisen K, Kristensen AT, Valentino LA, Hakobyan N, Ingerslev J, Tranholm M. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. J Thromb Haemost 2008, 6:969-75.
29. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004, 10:280-7.
30. Valentino LA, Hakobyan N, Kazarian T, Sorensen BB, Tranholm M. Prevention of haemarthrosis in a murine model of acute joint bleeding. Haemophilia 2009, 15:314-9.
31. Eckly A, Freund M, Zerr Fouineau M. Histological characterization of mouse carotid artery alteration following ferric chloride-induced injury. J Thromb Haemost 2009, 7:278. Abstract OC-TH-035
32. Øvlisen K, Kjalke M, Tranholm M. The effect of N8 and rFVIII on needle induced hemarthrosis in hemophilia a mice. J Thromb Haemost 2009, 7:823. Abstract PP-WE-581
33. Schlachterman A, Schuettrumpf J, Liu JH. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost 2005, 3:2730-7.
34. Gewirtz J, Thornton MA, Rauova L, Poncz M. Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J Thromb Haemost 2008, 6:1160-6.
35. Yarovoi HV, Kufrin D, Eslin DE. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood 2003, 102:4006-13.
36. Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood 2007, 109:2424-9.
37. Aljamali MN, Margaritis P, Schlachterman A. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 2008, 118:1825-34.
38. Gui T, Reheman A, Funkhouser WK. In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. Thromb Res 2007, 121:225-34.
39. Wang X, Cheng Q, Xu L. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005, 3:695-702.
40. Wang X, Xu L. An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res 2005, 115:95-100.
41. Smyth SS, Reis ED, Vaananen H, Zhang W, Coller BS. Variable protection of beta 3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood 2001, 98:1055-62.
42. Denis C, Methia N, Frenette PS. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998, 95:9524-9.